According to the WHO, in 2014, 1.9 million people were newly enrolled for anti-retroviral therapy, one of the largest annual increases. The WHO statistics also state that in 2014, 36.9 million individuals were living worldwide with HIV/AIDS and 1.2 million people died worldwide due to AIDS-related illnesses. Sub-Saharan Africa is the most severely affected; wherein around 1 in every 20 adults is living with HIV/AIDS. The WHO also estimates that only 54% people with HIV are aware of the infection they are suffering from.
Global Anti-Retroviral Drugs Market-Market Dynamics
The report details several factors driving and restraining the market, some of which are discussed below.
Some factors contributing to the growth of the market are:
Increasing investment in R&D of antivirals
Increasing expenditure on healthcare
High unmet need for efficacious drug
Rising prevalence rate of HIV and hepatitis
Some factors limiting the growth of the market are:
Increasing cost of R&D
Drugs going off patent
Increasing generic products
High cost of therapy
Combivir and Sustiva went off patent in 2012. Many other branded drugs such as Epivir, Ziagen, Invirase and others went off patent during 2009 and 2010. The current market lacks curative therapy and hence bringing innovative products and tapping the emerging economies will be a great opportunity for the market.
The anti-retroviral drugs market has been segmented based on the enzyme the drug targets and geography. Based on the enzyme the drug targets, the market has been segmented into protease inhibitors, non-nucleoside reverse transcriptase inhibitors, integrase inhibitors, nucleoside analogs and nucleoside reverse transcriptase inhibitors. The class of protease inhibitors includes the market for Indinavir, saquinavir, Lopinavir, Ritonavir, Nelfinavir, and Amprenavir. The class of non-nucleoside reverse transcriptase inhibitors includes the market for Delavirdine, Efavirenz, Nevirapine. The class of nucleoside analogs and nucleoside reverse transcriptase inhibitors include the market for Didanosine, Stavudine, Abacavir, Acyclovir, Zidovudine and their combination therapies. The class of integrase inhibitors includes Dolutegravir, Elvitegravir, Raltegravir and others. The new drugs such as Atripla are propelling the market growth to a great extent.
The report segments the market geographically into North America, Europe, Asia-Pacific, Middle East & Africa and South America. The North American region has been further segmented into the USA, Canada, and Mexico. The Europe region has been sub-divided into Germany, France, the UK, Spain, Italy, Scandinavia, Benelux and Rest of Europe. The Asia-Pacific market has been segmented into Japan, China, India, South Korea, Australia & New Zealand and Rest of Asia-Pacific. The Middle East & African market has been subdivided into GCC countries, South Africa and Rest of the Middle East and Africa. The South American market has been segmented into Brazil, Argentina, and Rest of South America. North America accounts for the largest market share.
Major Companies in the Sector Include:
This Report Offers:
Market analysis for the global anti-retroviral drugs market, with region-specific assessments and competition analysis.
Market definition along with the identification of key drivers and restraints.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their market share.
Identification and analysis of the macro and micro factors that affect the global anti-retroviral drugs market.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.
Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
1.1 Market definition
1.2 Study assumption
1.3 Report description
2. Research methodology
2.2 Analysis methodology
2.3 Study phases
2.3.1 Secondary research
2.3.2 Discussion guide
2.3.3 Market engineering &econometric modeling
2.3.4 Expert validation
2.4 Study timeline
3. Executive summary
4. Key inferences
5. Market dynamics
5.1 Market drivers
5.1.1 Increasing investment in R&D of antivirals
5.1.2 Increasing expenditure in healthcare
5.1.3 Rising prevalence rate of retroviral infections
5.1.4 High unmet needs
5.2 Market restraints
5.2.1 Increasing cost of R&D
5.2.2 Drugs going off-patent and simultaneous increasing generic products
5.2.3 High cost of therapy
5.3 Market opportunities
5.3.1 Innovative products
5.3.2 Emerging market
5.4 Market challenges
5.4.1 Lack of effective drugs
5.5 Porters' five forces
5.5.1 Bargaining power of suppliers
5.5.2 Bargaining power of buyers
5.5.3 Threat of substitutes
5.5.4 Threat of new entrants
5.5.5 Competitive rivalry
6. Market segmentation
6.1.1 Protease Inhibitors
6.1.2 Non-Nucleoside reverse transcriptase inhibitors
6.1.3 Nucleoside analogs and nucleoside reverse transcriptase inhibitors
6.1.4 Integrase Inhibitors
7. Market segmentation by geography
7.1 North America
7.2.8 Rest of Europe
7.3.4 Australia & New Zealand
7.3.5 Rest of Asia-Pacific
7.4 Middle East & Africa
7.4.2 South Africa
7.4.3 Rest of the Middle East & Africa
7.5 South America
7.5.3 Rest of South America
8. Competitive landscape
8.1 New product launches
8.2 Mergers and acquisitions
8.3 Agreement, collaboration and partnerships
9. Company profiles
9.8 Johnson and Johnson
9.9 Boehringer Ingelheim
9.10 Novartis AG
10. Future outlook of the market